Marksans Pharma Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings
- October 9, 2026
- Posted by: Neeraj Pandey
- Category: Market
Marksans Pharma share price Rs 309.10 (9 October 2026). Base target Rs 355, bull Rs 430, downside risk Rs 246. PE 26.77. 52W range Rs 155.00 to Rs 350.95.
Quick Answer
The Marksans Pharma share price target for 2027 is Rs 355, about 14.8% above the current price of Rs 309.10. The bull case is Rs 430, and the downside risk level, which is not a target, is Rs 246. The base case assumes earnings per share grow 15.4% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 26.77. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Marksans Pharma target price for 2027 should start with where the stock sits today. At Rs 309.10 on 9 October 2026, it is 11.9% below its 52-week high of Rs 350.95 and 99.4% above its 52-week low of Rs 155.00. That range spans 126% from low to high, so the entry point matters as much as the Marksans Pharma price forecast itself.
This article builds the Marksans Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 355 base case and the Rs 430 bull case were reached, along with a downside risk level of Rs 246.
Click Here – Get Free Investment Predictions
Marksans Pharma Stock Analysis: Company Overview and Key Stats
Marksans Pharma (NSE: MARKSANS) has a market capitalisation of Rs 13,953 crore. In FY26 it reported revenue of Rs 3,033 crore and net profit of Rs 420.06 crore. The table collects the figures the Marksans Pharma share price target is built on.
| Metric | Value |
|---|---|
| Company | Marksans Pharma |
| NSE Ticker | MARKSANS |
| CMP (9 October 2026) | Rs 309.10 |
| 52-Week High | Rs 350.95 |
| 52-Week Low | Rs 155.00 |
| Market Cap | Rs 13,953 crore |
| PE Ratio (TTM) | 26.77 |
| Industry PE | 37.59 |
| Price to Book | 4.62 |
| Return on Equity | 13.82% |
| Debt to Equity | 0.11 |
| EPS (TTM) | Rs 11.50 |
| Dividend Yield | 0.29% |
| 12-Month Base Target | Rs 355 |
| Bull Case | Rs 430 |
| Downside Risk Level (not a target) | Rs 246 |
Why Is Marksans Pharma Share Price Target Set at Rs 355 for 2027?
The base-case Marksans Pharma stock target of Rs 355 applies a PE multiple of 26.77 to a forward EPS estimate of Rs 13.27. That EPS assumes 15.4% yearly growth, the pace from FY24 to FY26, and puts the target 14.8% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Marksans Pharma Target Price: Five Years of Results
Marksans Pharma grew revenue from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew faster, from Rs 186.81 crore to Rs 420.06 crore (22.5% a year), which shows margin gains did part of the work and not just higher sales.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 1,532.69 | 186.81 | 4.51 | 0.25 |
| FY23 | 1,911.45 | 265.32 | 6.41 | 0.50 |
| FY24 | 2,227.83 | 314.89 | 6.92 | 0.60 |
| FY25 | 2,689.17 | 382.62 | 8.40 | 0.80 |
| FY26 | 3,033.47 | 420.06 | 9.22 | 0.90 |
FY26 revenue growth was 12.8%, slower than the four-year average of 18.6%, and net profit moved up 9.8%. EPS rose from Rs 6.92 in FY24 to Rs 9.22 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Marksans Pharma converted 13.8% of FY26 revenue into net profit, against 14.2% in FY25, within a five-year range of 12.2% to 14.2%. EBITDA margin was 22.5% in FY26 versus 22.3% in FY25.
In the June 2026 quarter, revenue was Rs 866.20 crore, up 38.5% from the same quarter a year earlier, while net profit of Rs 159.41 crore was up 173.9%. EBITDA came in at Rs 238.44 crore, up 125.5% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.11, and shareholders’ equity grew from Rs 1,223 crore in FY22 to Rs 3,053 crore in FY26. Operating cash flow in FY26 was Rs 458.13 crore against capital expenditure of Rs 130.53 crore, leaving free cash flow of Rs 327.60 crore, or 2.3% of the current market capitalisation. In FY25 free cash flow was Rs 33.74 crore.
Valuation Check for the Marksans Pharma Stock Target: PE, Price to Book and ROE
At a PE of 26.77 against an industry PE of 37.59, Marksans Pharma trades at a discount to its industry. Price to book is 4.62 on a book value of Rs 66.71 per share, and return on equity is 13.82%. A PE of 26.77 equals an earnings yield of 3.7%, and the FY26 dividend of Rs 0.90 per share gives a yield of 0.29%.
Shareholding Pattern and Institutional Holding
Promoters held 43.87% of Marksans Pharma in June 2026, and promoter holding has stayed near 43.87% since June 2025. Foreign institutional investors (FII) held 17.47% and domestic institutions (DII) held 6.19%, which puts total institutional holding at 23.66%. FII holding fell from 19.88% in June 2025 to 17.47% in June 2026. Public shareholders own the remaining 32.47%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Marksans Pharma Share Price Targets for the Short Term and 12 Months
Short Term Marksans Pharma Stock Target Levels: Technical Setup
At Rs 309.10 on 9 October 2026, Marksans Pharma trades below its 50-day simple moving average of Rs 315.92 and above its 200-day exponential moving average of Rs 256.21. The 14-day RSI reads 45.3, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 315.92 (50-day simple moving average) and the nearest support is Rs 256.21 (200-day exponential moving average). A sustained move above Rs 315.92 would improve the short-term setup, while a close below Rs 256.21 would shift attention to the next support.
12 Month Marksans Pharma Target Price for 2027
The 12-month target for Marksans Pharma is Rs 355: forward EPS of Rs 13.27 at a PE of 26.77. That is 14.8% above Rs 309.10. It would also push the stock above its 52-week high of Rs 350.95.
How EPS Growth and PE Multiple Change the Marksans Pharma Target Price
| EPS Growth | PE 21.42 | PE 26.77 | PE 30.79 |
|---|---|---|---|
| 0.0% (EPS Rs 11.50) | Rs 246 | Rs 308 | Rs 354 |
| 15.4% (EPS Rs 13.27) | Rs 284 | Rs 355 | Rs 409 |
| 21.4% (EPS Rs 13.96) | Rs 299 | Rs 374 | Rs 430 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Marksans Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Marksans Pharma Stock Target in 2027
Bull Case Rs 430
The bull case Marksans Pharma price target needs EPS growth of 21.4%, which lifts forward EPS to Rs 13.96, and a PE multiple that rises 15% to 30.79. That gives Rs 430, 39.1% above the current price and above the 52-week high of Rs 350.95, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 246
The downside risk level is not a target. It assumes EPS stays flat at Rs 11.50 and the PE falls 20% to 21.42. That gives Rs 246, 20.4% below the current price and above the 52-week low of Rs 155.00.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 21.4% | 30.79 | Rs 430 | +39.1% |
| Base Case | 15.4% | 26.77 | Rs 355 | +14.8% |
| Downside Risk | 0.0% | 21.42 | Rs 246 | -20.4% |
Key Risks to the Marksans Pharma Target Price for 2027
Growth Slowdown Risk for the Marksans Pharma Price Target
Revenue in the June 2026 quarter was up 38.5% year on year, and FY26 revenue growth was 12.8%. If growth slows from here, the EPS estimate behind the Marksans Pharma stock target will need revising.
Liquidity and Size Risk
Marksans Pharma has a market capitalisation of Rs 13,953 crore. Institutional holding is 23.66%, and promoters hold 43.87%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 13.8% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 26.77 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 21.42 would cut the price even if earnings hold.
Market and Technical Risk
The stock trades 11.9% below its 52-week high, with an RSI of 45.3 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.
How to Invest in Marksans Pharma
Start with the live price and volume. Any Marksans Pharma share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 309.10 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Marksans Pharma’s PE, ROE, debt and shareholding in one place.
Check Marksans Pharma fundamentals on the Univest Screener
Then compare the three Marksans Pharma target price scenarios with your own view. If you expect EPS growth below 15.4%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Marksans Pharma live price and get daily stock recommendations.
Conclusion
The Marksans Pharma share price target for 2027 is Rs 355 in the base case, with Rs 430 as the bull case. The support for that view is arithmetic you can check: EPS grew 15.4% a year over FY24 to FY26, and the stock trades at a PE of 26.77. The risks are equally concrete, including a stock that sits 11.9% below its 52-week high and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Marksans Pharma Share Price Target 2027
What is the Marksans Pharma share price target for 2027?
Ans. The base-case Marksans Pharma share price target for 2027 is Rs 355, with Rs 430 as the bull case. The downside risk level, which is not a target, is Rs 246. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.
What is the Marksans Pharma share price today?
Ans. As of 9 October 2026, 3:30 PM IST, Marksans Pharma trades at Rs 309.10, up 0.42% on the day. The 52-week range is Rs 155.00 to Rs 350.95.
Is Marksans Pharma a buy or sell at the current price?
Ans. The data is mixed rather than one-sided: EPS has grown 15.4% a year over FY24 to FY26, but the stock is 11.9% below its 52-week high. Whether Marksans Pharma fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.
What are the bull case target and downside risk level for Marksans Pharma shares?
Ans. The bull case target is Rs 430, which assumes 21.4% EPS growth and a PE of 30.79. The downside risk level is Rs 246, which assumes flat EPS and a PE of 21.42. It marks a risk, not a target.
What are the main risks to the Marksans Pharma price target?
Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 13,953 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.
What is the PE ratio of Marksans Pharma and how does it compare with the industry?
Ans. The PE ratio of Marksans Pharma is 26.77 against an industry PE of 37.59. Price to book is 4.62 and return on equity is 13.82%. The base case in the Marksans Pharma price target holds this PE constant.
Who owns Marksans Pharma, and what is the promoter holding?
Ans. Promoters held 43.87% of Marksans Pharma in June 2026. FII held 17.47%, DII held 6.19% and the public held 32.47%.
What were Marksans Pharma’s latest quarterly results?
Ans. In the June 2026 quarter, Marksans Pharma reported revenue of Rs 866.20 crore (up 38.5% year on year) and net profit of Rs 159.41 crore (up 173.9%).
